The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial
暂无分享,去创建一个
E. Hoster | W. Hiddemann | U. Dührsen | M. Dreyling | B. Wörmann | A. Neubauer | B. Metzner | H. Wandt | M. Unterhalt | H. Eimermacher | S. Martin | H. Steinhauer | E. Heidemann | A. Aldaoud